The anemia in chronic kidney disease market has been comprehensively analyzed in IMARC's new report titled "Anemia in Chronic Kidney Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Anemia in chronic kidney disease (CKD) is a prevalent complication characterized by a deficiency in red blood cells or hemoglobin. Hemoglobin plays a crucial role in transporting oxygen throughout the body, and its reduced levels in CKD patients can lead to fatigue, weakness, and shortness of breath. As the kidneys function to produce erythropoietin, a hormone essential for red blood cell production, their impairment in CKD contributes to anemia. Symptoms may also include pale skin, dizziness, and cold hands and feet. Diagnosing anemia in CKD involves blood tests to assess hemoglobin and other related parameters such as hematocrit and mean corpuscular volume. Additionally, healthcare providers may evaluate serum ferritin and transferrin saturation to determine iron status, a key factor in addressing anemia. Timely identification and management of anemia in CKD are crucial to enhance patients' quality of life and mitigate the risk of cardiovascular complications associated with inadequate oxygen delivery to tissues.
The escalating incidence of impaired kidney function that can affect the absorption and regulation of iron, leading to reduced iron availability for the production of hemoglobin, is primarily driving the anemia in the chronic kidney disease market. In addition to this, the inflating utilization of effective medications such as beta-blockers, carbonic anhydrase inhibitors, and prostaglandin analogs, which play a crucial role in managing the condition and thwarting further damage, is creating a positive outlook for the market. Moreover, the widespread adoption of physical and occupational therapies that help in strengthening muscles, improving coordination, and enhancing gross motor skills, is also bolstering the market growth. Apart from this, the rising usage of pulsed dye laser procedures, targeting abnormal blood vessels to selectively destroy and lighten affected skin areas, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of gene therapy, a novel approach involving the introduction of functional genetic material into cells to replace or correct mutated or malfunctioning genes responsible for the disease, is expected to drive the anemia in the chronic kidney disease market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the anemia in chronic kidney disease market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for anemia in chronic kidney disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the anemia in chronic kidney disease market in any manner.
Time Period of the Study
Countries Covered
Analysis Covered Across Each Country
This report also provides a detailed analysis of the current anemia in chronic kidney disease marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Late-Stage Pipeline Drugs
Drugs | Company Name |
---|---|
Epogen (Epoetin alfa ) | Kyowa Kirin-Amgen |
Aranesp (Darbepoetin alfa) | Kyowa Kirin-Amgen |
Jesduvroq (Daprodustat) | GlaxoSmithKline |
Vafseo (Vadadustat) | Akebia Therapeutics |
DISC-0974 | Disc Medicine |
AND017 | Kind Pharmaceuticals |
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Market Insights
Epidemiology Insights
Anemia In Chronic Kidney Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies